{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:06:35Z","timestamp":1782759995048,"version":"3.54.5"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"Background<\/jats:title>Helicobacter pylori<\/jats:italic> (H. pylori<\/jats:italic>) is highly prevalent worldwide and is closely associated with many gastric conditions. Current methods for eradicating H. pylori<\/jats:italic> include triple or quadruple therapy, including antibiotics, proton pump inhibitors, and bismuth agents; however, with antibiotic abuse and increased drug resistance rates, the effectiveness of traditional methods is gradually decreasing, with many adverse effects such as abdominal pain, diarrhea, and intolerance. In recent years, there has been controversy regarding whether adding Saccharomyces boulardii<\/jats:italic> (S. boulardii<\/jats:italic>) to traditional therapies is beneficial for eradicating H. pylori<\/jats:italic>.<\/jats:p><\/jats:sec>Aim<\/jats:title>To evaluate the efficacy and safety of S. boulardii<\/jats:italic> as an adjuvant therapy for the eradication of H. pylori<\/jats:italic>.<\/jats:p><\/jats:sec>Methods<\/jats:title>We systematically searched the PubMed and Web of Science databases from January 2002 to January 2023. The primary outcome was the H. pylori<\/jats:italic> eradication rate. The secondary outcomes included total adverse effects, abdominal pain, diarrhea, bloating, constipation, nausea, vomiting, taste disorders, and other adverse reactions. We evaluated the included studies for publication bias and heterogeneity. Fixed- and random-effects models were used for studies without and with heterogeneity, respectively, to calculate the risk ratios (RRs) and conduct sensitivity and subgroup analyses.<\/jats:p><\/jats:sec>Results<\/jats:title>Nineteen studies comprising 5,036 cases of H. pylori<\/jats:italic> infection were included in this meta-analysis. The addition of S. boulardii<\/jats:italic> to traditional therapy significantly improved the H. pylori<\/jats:italic> eradication rate [RR=1.11, 95% confidence interval (CI): 1.08\u20131.15] and reduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37\u20130.66), diarrhea (RR=0.36, 95% CI: 0.26\u20130.48), abdominal distension (RR=0.49, 95% CI: 0.33\u20130.72), constipation (RR=0.38, 95% CI: 0.26\u20130.57), and nausea (RR=0.50, 95% CI: 0.37\u20130.68). However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>S. boulardii<\/jats:italic> supplementation in traditional eradication therapy significantly improves the H. pylori<\/jats:italic> eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.<\/jats:p><\/jats:sec>Systematic review registration<\/jats:title>Prospero, identifier CRD42024549780.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2025.1441185","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:28:09Z","timestamp":1739345289000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication of Helicobacter pylori: a meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Manning","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5223\/pghn.2015.18.1.17","article-title":"The Efficacy of Saccharomyces boulardii CNCM I-745 in Addition to Standard Helicobacter pylori Eradication Treatment in Children","volume":"18","author":"Bin","year":"2015","journal-title":"Pediatr. Gastroenterol. Hepatol. Nutr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/BF01536771","article-title":"Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces Boulardii","volume":"35","author":"Buts","year":"1990","journal-title":"Dig Dis. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3904\/kjim.2019.139","article-title":"Effects of probiotics or broccoli supplementation on Helicobacter pylori eradication with standard clarithromycin-based triple therapy","volume":"35","author":"Chang","year":"2020","journal-title":"Korean J. Intern. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.22034\/apjcp.2017.18.10.2839","article-title":"Effectiveness of 7-day and 14-day moxifloxacin-dexlansoprazole based triple therapy and probiotic supplement for helicobacter pylori eradication in Thai patients with non-ulcer dyspepsia: A double-blind randomized placebo-controlled study","volume":"18","author":"Chotivitayatarakorn","year":"2017","journal-title":"Asian Pac J. Cancer Prev."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12870","article-title":"Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during Helicobacter pylori eradication therapy","volume":"27","author":"Cifuentes","year":"2022","journal-title":"Helicobacter"},{"key":"B6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1523-5378.2007.00516.x","article-title":"Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study","volume":"12","author":"Cindoruk","year":"2007","journal-title":"Helicobacter"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1111\/j.1572-0241.2002.07063.x","article-title":"Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study","volume":"97","author":"Cremonini","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1128\/IAI.71.2.766-773.2003","article-title":"Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells","volume":"71","author":"Dahan","year":"2003","journal-title":"Infect. Immun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1097\/00042737-200512000-00015","article-title":"Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication","volume":"17","author":"Duman","year":"2005","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1080\/17474124.2018.1496017","article-title":"Helicobacter pylori drug resistance: therapy changes and challenges","volume":"12","author":"Flores-Trevi\u00f1o","year":"2018","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4321\/s1130-01082012000900005","article-title":"Low co-existence rates of Lactobacillus spp. and Helicobacter pylori detected in gastric biopsies from patients with gastrointestinal symptoms","volume":"104","author":"Garc\u00eda","year":"2012","journal-title":"Rev. Esp Enferm Dig"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3760\/cma.j.issn.0376-2491.2019.22.010","article-title":"Influence of different timing of Saccharomyces boulardii combined with bismuth quadruple therapy for Helicobacter pylori eradication","volume":"99","author":"He","year":"2019","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.13381\/j.cnki.cjm.201902011","article-title":"Saccharomyces boulardii combined with triple therapy in treatment of Helicobacter pylori infection in children: A clinical observation","volume":"31","author":"He","year":"2019","journal-title":"Chin. J. Microecology"},{"key":"B14","first-page":"289","article-title":"Sixth Chinese National Consensus report on management of Helicobacter pylori infection (treatment rxcluded)","volume":"27","year":"2022","journal-title":"Chin J Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1651-2227.2008.00977.x","article-title":"A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children","volume":"98","author":"Hurduc","year":"2009","journal-title":"Acta Paediatr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/mcg.0000000000001719","article-title":"Helicobacter pylori world gastroenterology organization global guideline","volume":"57","author":"Katelaris","year":"2023","journal-title":"J. Clin. Gastroenterol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s00284-020-02053-9","article-title":"Saccharomyces boulardii CNCM I-745: A non-bacterial microorganism used as probiotic agent in supporting treatment of selected diseases","volume":"77","author":"Ka\u017amierczak-Siedlecka","year":"2020","journal-title":"Curr. Microbiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/jam.14037","article-title":"Application of Saccharomyces cerevisiae var. boulardii in food processing: a review","volume":"125","author":"Lazo-V\u00e9lez","year":"2018","journal-title":"J. Appl. Microbiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infection\u2013the Maastricht IV\/Florence Consensus Report","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.3748\/wjg.v16.i18.2202","article-title":"Systematic review and meta-analysis of Saccharomyces boulardii in adult patients","volume":"16","author":"McFarland","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/ijerph191912847","article-title":"Multicentric study to assess helicobacter pylori incidence, patient reported adverse events, compliance and effectiveness, in real-world setting","volume":"19","author":"Mesquita","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12876-022-02187-z","article-title":"Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial","volume":"22","author":"Naghibzadeh","year":"2022","journal-title":"BMC Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e3768","DOI":"10.5812\/ijp.3768","article-title":"Saccharomyces boulardii in helicobacter pylori eradication in children: A randomized trial from Iran","volume":"26","author":"Namkin","year":"2016","journal-title":"Iran J. Pediatr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/jof6020078","article-title":"Saccharomyces boulardii: what makes it tick as successful probiotic","volume":"6","author":"Pais","year":"2020","journal-title":"J. Fungi (Basel)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.4161\/gmic.27169","article-title":"Introduction. Helicobacter pylori","volume":"4","author":"Peek","year":"2013","journal-title":"Gut Microbes"},{"key":"B26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/jgh.15751","article-title":"Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis","volume":"37","author":"Ren","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/apm.12237","article-title":"Saccharomyces boulardii expresses neuraminidase activity selective for \u03b12,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells","volume":"122","author":"Sakarya","year":"2014","journal-title":"Apmis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00228-019-02625-0","article-title":"Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial","volume":"75","author":"Seddik","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1523-5378.2010.00751.x","article-title":"The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori","volume":"15","author":"Song","year":"2010","journal-title":"Helicobacter"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7919","DOI":"10.1111\/jcmm.14682","article-title":"Helicobacter pylori recrudescence and its influencing factors","volume":"23","author":"Sun","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/apt.13214","article-title":"Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection","volume":"41","author":"Szajewska","year":"2015","journal-title":"Aliment Pharmacol. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/nu14030632","article-title":"A four-probiotics regimen combined with A standard helicobacter pylori-eradication treatment reduces side effects and increases eradication rates","volume":"14","author":"Viazis","year":"2022","journal-title":"Nutrients"},{"key":"B33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.13381\/j.cnki.cjm.201501014","article-title":"Effectiveness of different courses of Saccharomyces boulardii therapy in Helicobacter pylori eradication","volume":"27","author":"Wang","year":"2015","journal-title":"Chin. J. Microecology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3760\/cma.j.cn112137-20210811-01790","article-title":"A multi-center, randomized controlled study on the effect of Saccharomyces boulardii combined with triple therapy for the initial eradication of Helicobacter pylori infection","volume":"102","author":"Yang","year":"2022","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.3748\/wjg.v20.i18.5283","article-title":"Treatment of Helicobacter pylori infection: current status and future concepts","volume":"20","author":"Yang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B36","first-page":"230","article-title":"Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children","volume":"16","author":"Zhao","year":"2014","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.776955","article-title":"Saccharomyces boulardii Combined With Quadruple Therapy for Helicobacter pylori Eradication Decreased the Duration and Severity of Diarrhea: A Multi-Center Prospective Randomized Controlled Trial","volume":"8","author":"Zhao","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12651","article-title":"Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis","volume":"24","author":"Zhou","year":"2019","journal-title":"Helicobacter"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.3760\/cma.j.issn.0376-2491.2017.30.008","article-title":"Influence of Saccharomyces boulardii Sachets combined with bismuth quadruple therapy for initial Helicobacter pylori eradication","volume":"97","author":"Zhu","year":"2017","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.3760\/cma.j.issn.0376-2491.2018.28.007","article-title":"Influence of two kinds of probiotics combined with bismuth quadruple therapy for Helicobacter pylori eradication","volume":"98","author":"Zhu","year":"2018","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B41","first-page":"S99","article-title":"The efficacy and safety of adding the probiotic Saccharomyces boulardiito standard triple therapy for eradication of H.pylori: a randomized controlled trial","volume":"6","author":"Zojaji","year":"2013","journal-title":"Gastroenterol. Hepatol. Bed Bench"},{"key":"B42","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1046\/j.1365-2036.2003.01461.x","article-title":"High eradication rates of Helicobacter pylori with a new sequential treatment","volume":"17","author":"Zullo","year":"2003","journal-title":"Aliment Pharmacol. Ther."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1441185\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:28:17Z","timestamp":1739345297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1441185\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":42,"alternative-id":["10.3389\/fcimb.2025.1441185"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1441185","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"article-number":"1441185"}}